No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial

Background Lipoatrophy can complicate thymidine analogue nucleoside reverse transcriptase inhibitor (tNRTI)‐based antiretroviral therapy (ART). Lipoatrophy may be less likely with ART including ritonavir‐boosted lopinavir (LPV/r). Small, placebo‐controlled studies found that uridine (in tNRTI recipi...

Full description

Saved in:
Bibliographic Details
Published in:HIV medicine 2010-09, Vol.11 (8), p.493-501
Main Authors: Calmy, A, Bloch, M, Wand, H, Delhumeau, C, Finlayson, R, Rafferty, M, Norris, R, Hirschel, B, Cooper, DA, Carr, A
Format: Article
Language:English
Subjects:
Absorptiometry, Photon
Adiposity - drug effects
Adult
Anti-Retroviral Agents - adverse effects
Anti-Retroviral Agents - therapeutic use
Anticholesteremic Agents - pharmacokinetics
Anticholesteremic Agents - pharmacology
Anticholesteremic Agents - therapeutic use
antiretroviral therapy
Clinical trials
Dideoxynucleosides - adverse effects
Drug Therapy, Combination
Extremities
HIV Infections - complications
HIV Infections - drug therapy
HIV lipoatrophy
HIV-Associated Lipodystrophy Syndrome - chemically induced
HIV-Associated Lipodystrophy Syndrome - drug therapy
Human immunodeficiency virus
Humans
limb fat
lipoatrophy
Lopinavir
Male
Middle Aged
nucleoside analogs
nucleoside reverse transcriptase inhibitors
pravastatin
Pravastatin - pharmacokinetics
Pravastatin - pharmacology
Pravastatin - therapeutic use
Pyrimidinones - therapeutic use
Reverse Transcriptase Inhibitors - adverse effects
Ritonavir - therapeutic use
Thymidine
Uridine
Uridine - pharmacokinetics
Uridine - pharmacology
Uridine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Lipoatrophy can complicate thymidine analogue nucleoside reverse transcriptase inhibitor (tNRTI)‐based antiretroviral therapy (ART). Lipoatrophy may be less likely with ART including ritonavir‐boosted lopinavir (LPV/r). Small, placebo‐controlled studies found that uridine (in tNRTI recipients) and pravastatin improved HIV lipoatrophy over 12 weeks. Today, most patients with lipoatrophy receive non‐tNRTI‐based ART; the effect of uridine in such patients is unknown. Methods We performed a prospective, randomized trial in lipoatrophic adults with plasma HIV RNA
ISSN:1464-2662
1468-1293
DOI:10.1111/j.1468-1293.2009.00817.x